•$Verve Therapeutics (VERV.US)$+1.8% (reports durable and well-tolerated editing of ANGPTL3 gene out to more than 20 months in non-human primates for potential treatment of atherosclerotic cardiovascular disease)
•$BridgeBio Pharma (BBIO.US)$+1.4% (Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy)
•$Lexicon Pharmaceuticals (LXRX.US)$+1.3% (reports Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session)
•$Alnylam Pharmaceuticals (ALNY.US)$-1.9% (FDA has extended the review timeline of the New Drug Application for vutrisiran to allow for the review of newly added information related to the new secondary packaging and labeling facility)
•$FREYR Battery (FREY.US)$-1.2% (announced the appointment of Oscar Brown to the position of Group Chief Financial Officer at FREYR Battery)
Analyst comments:
•$Hologic (HOLX.US)$-2.4% (downgraded to In-line from Outperform at Evercore ISI)
ngwah :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
71651324 : #hypebeast Thursday!
RDK79 : Glad I unloaded my SBUX a couple months ago.
Silverbat : Will be strangled slowly by the acute inflation and sagging markets.